Abstract
Endogenous retroviruses (ERVs) are genomic sequences that originated from retroviruses and are present in most eukaryotic genomes. Both beneficial and detrimental functions are attributed to ERVs, but whether ERVs contribute to antiviral immunity is not well understood. Here, we used herpes simplex virus type 2 (HSV-2) infection as a model and found that Toll-like receptor 7 (Tlr7 -/-) deficient mice that have high systemic levels of infectious ERVs are protected from intravaginal HSV-2 infection and disease, compared to wildtype C57BL/6 mice. We deleted the endogenous ecotropic murine leukemia virus (Emv2) locus on the Tlr7 -/- background (Emv2 -/- Tlr7 -/-) and found that Emv2 -/- Tlr7 -/- mice lose protection against HSV-2 infection. Intravaginal application of purified ERVs from Tlr7-/- mice prior to HSV-2 infection delays disease in both wildtype and highly susceptible interferon-alpha receptor-deficient (Ifnar1- /-) mice. However, intravaginal ERV treatment did not protect Emv2-/-Tlr7-/- mice from HSV-2 disease, suggesting that the protective mechanism mediated by exogenous ERV treatment may differ from that of constitutively and systemically expressed ERVs in Tlr7-/- mice. We did not observe enhanced type I interferon (IFN-I) signaling in the vaginal tissues from Tlr7-/- mice, and instead found enrichment in genes associated with extracellular matrix organization. Together, our results revealed that constitutive and/or systemic expression of ERVs protect mice against vaginal HSV-2 infection and delay disease.
Highlights
Genital herpes simplex virus 2 (HSV-2) is a common cause of sexually transmitted infection (STI) and affects 491.5 million individuals worldwide, equivalent to 13.2% of the world population ages 15 to 49 [1]
Total leukocytes from the spleen, bone marrow, colon and the lung were co-cultured with susceptible avian DFJ8 cells, and Endogenous retroviruses (ERVs) envelope expression was measured on DFJ8 cells (Figure 1A)
We investigated whether systemic expression of infectious ERVs would influence antiviral responses and monitored outcomes to intravaginal herpes simplex virus type 2 (HSV-2) infection in WT and Tlr7-/
Summary
Genital herpes simplex virus 2 (HSV-2) is a common cause of sexually transmitted infection (STI) and affects 491.5 million individuals worldwide, equivalent to 13.2% of the world population ages 15 to 49 [1]. HSV-2 enters through epithelial cells of the skin and mucosal linings of the genital area. Reactivation of HSV-2 occurs during stress and can cause blisters and lesions, itchiness, pain and shedding of the virus [2, 3]. Epithelial cell damage caused by HSV-2 infection and reactivation results in STI coinfections, including human immunodeficiency virus (HIV) and hepatitis C virus (HCV) [3]. There is a higher incidence of bacterial vaginosis and encephalitis in HSV-2 positive individuals [5].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
